MacroGenics (NASDAQ: MGNX)
MacroGenics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
MacroGenics Company Info
MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
News & Analysis
MacroGenics Revenue Doubles in Q2
Why Shares of MacroGenics Are Jumping Thursday
The company announced second-quarter earnings.
Why MacroGenics Stock Inched Higher on Monday
A pair of more-bullish analyst evaluations gave hope to investors.
Why MacroGenics Stock Tumbled Today
The company had quite a comedown shortly after releasing its latest set of annual results.
Why Shares of MacroGenics Climbed Thursday
The cancer-focused biotech delivered a strong earnings report.
Why Shares of MacroGenics Jumped Thursday
The company made a sale worth as much as $200 million for the royalty rights for its type-1 diabetes therapy.
Why Shares of MacroGenics Were Dropping Tuesday
Profit-taking and an analyst downgrade affected the stock's price.
Why MacroGenics Stock Crushed the Market on Monday
Positive momentum continues for the cancer specialist in the wake of its latest earnings report.
Valuation
Earnings Transcripts
MacroGenics (MGNX) Q4 2024 Earnings Call Transcript
MGNX earnings call for the period ending December 31, 2024.
MacroGenics (MGNX) Q3 2024 Earnings Call Transcript
MGNX earnings call for the period ending September 30, 2024.
MacroGenics (MGNX) Q1 2024 Earnings Call Transcript
MGNX earnings call for the period ending March 31, 2024.
MacroGenics (MGNX) Q4 2023 Earnings Call Transcript
MGNX earnings call for the period ending December 31, 2023.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.